Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Series
Series
ESMO Early Breast Cancer
ADC Therapy Treatment HER2+ and HER2-Low mBC
IWTI Best Practices in GU Navigation
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC
Authored Items
A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Quality of Life with Combination Therapy in Advanced Renal-Cell Cancer
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
The Impact of Real-World Data on Efficacy and Safety of Agents for Advanced Renal-Cell Cancer
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Educating Patients About First-Line Treatment Options for Advanced Renal-Cell Carcinoma
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Advanced Care Practitioners Take a Lead in Improving Quality of Life and Patient Satisfaction for Cancer Patients
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Talking to Cancer Patients About Combination Chemotherapy
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Advanced Care Practitioners Have Best Practices to Help Patients Be Compliant with Their Chemotherapy
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Patient Education Is a Critical Role for the Nurse Navigator and Advanced Care Practitioner
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Combination Therapy in Renal-Cell Carcinoma and Quality of Life
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
The Multidisciplinary Care Approach to Cancer Care Management
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
The Clinical Advantages of Combination Therapies in Advanced RCC
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Improving the Patient Experience by Helping Patients Navigate Their Cancer Care
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Videos
in
Interview with the Innovators
Last modified: May 27, 2021
